Role of pyroptosis in nonalcoholic fatty liver disease

Jingya YIN; Bingqing YANG; Yue LI

doi:10.3969/j.issn.1001-5256.2023.01.027

Volume 39 Issue 1

Jan. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(1): 175-180

PDF( 2197 KB)

Role of pyroptosis in nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.01.027

Jingya YIN^a,
Bingqing YANG^a,
Yue LI^{b
,
,
,}

a.
Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
b.
Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

Research funding:

National Natural Science Foundation of China (82000555)

More Information

Corresponding author: LI Yue, liyuedl04@126.com (ORCID: 0000-0002-7412-7632)
Received Date: 2022-05-02
Accepted Date: 2022-07-25
Published Date: 2023-01-20

Abstract

Abstract

As a novel mode of cell death, pyroptosis plays an important role in nonalcoholic fatty liver disease (NAFLD), and the research on pyroptosis may help to explore new therapeutic targets for NAFLD. This article reviews the advances in pyroptosis from the research background and mechanism of pyroptosis and the role of pyroptosis in NAFLD and elaborates on the pyroptosis execution molecules such as GSDME and caspase-11 and the function of inflammasomes including AIM2.
- Non-alcoholic Fatty Liver Disease,
- Pyroptosis,
- Inflammasomes

FullText(HTML)

References(45)

References

[1]	POWELL EE, WONG VW, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224. DOI: 10.1016/S0140-6736(20)32511-3.
[2]	LI J, ZOU B, YEO YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398. DOI: 10.1016/S2468-1253(19)30039-1.
[3]	YAN J, XIE W, OU WN, et al. Epidemiological survey and risk factor analysis of fatty liver disease of adult residents, Beijing, China[J]. J Gastroenterol Hepatol, 2013, 28(10): 1654-1659. DOI: 10.1111/jgh.12290.
[4]	KUANG S, ZHENG J, YANG H, et al. Structure insight of GSDMD reveals the basis of GSDMD autoinhibition in cell pyroptosis[J]. Proc Natl Acad Sci U S A, 2017, 114(40): 10642-10647. DOI: 10.1073/pnas.1708194114.
[5]	XIAO WS, LE YY, ZENG SL, et al. Role of pyroptosis in liver diseases[J]. J Clin Hepatol, 2020, 36(12): 2847-2850. DOI: 10.3969/j.issn.1001-5256.2020.12.044. 肖伟松, 乐滢玉, 曾胜澜, 等. 细胞焦亡在肝脏疾病中的作用[J]. 临床肝胆病杂志, 2020, 36(12): 2847-2850. DOI: 10.3969/j.issn.1001-5256.2020.12.044.
[6]	PUGLIESE N, PLAZ TORRES MC, PETTA S, et al. Is there an 'ideal' diet for patients with NAFLD?[J]. Eur J Clin Invest, 2022, 52(3): e13659. DOI: 10.1111/eci.13659.
[7]	BOISE LH, COLLINS CM. Salmonella-induced cell death: apoptosis, necrosis or programmed cell death?[J]. Trends Microbiol, 2001, 9(2): 64-67. DOI: 10.1016/s0966-842x(00)01937-5.
[8]	SHI J, ZHAO Y, WANG K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death[J]. Nature, 2015, 526(7575): 660-665. DOI: 10.1038/nature15514.
[9]	KAYAGAKI N, STOWE IB, LEE BL, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling[J]. Nature, 2015, 526(7575): 666-671. DOI: 10.1038/nature15541.
[10]	HIRSOVA P, GORES GJ. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis[J]. Cell Mol Gastroenterol Hepatol, 2015, 1(1): 17-27. DOI: 10.1016/j.jcmgh.2014.11.005.
[11]	D'ARCY MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy[J]. Cell Biol Int, 2019, 43(6): 582-592. DOI: 10.1002/cbin.11137.
[12]	YAN J, WAN P, CHOKSI S, et al. Necroptosis and tumor progression[J]. Trends Cancer, 2022, 8(1): 21-27. DOI: 10.1016/j.trecan.2021.09.003.
[13]	BATTAGLIA AM, CHIRILLO R, AVERSA I, et al. Ferroptosis and cancer: Mitochondria meet the "iron maiden" cell death[J]. Cells, 2020, 9(6): 1505. DOI: 10.3390/cells9061505.
[14]	THIAM HR, WONG SL, WAGNER DD, et al. Cellular mechanisms of NETosis[J]. Annu Rev Cell Dev Biol, 2020, 36: 191-218. DOI: 10.1146/annurev-cellbio-020520-111016.
[15]	SARHAN J, LIU BC, MUENDLEIN HI, et al. Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during Yersinia infection[J]. Proc Natl Acad Sci U S A, 2018, 115(46): E10888-E10897. DOI: 10.1073/pnas.1809548115.
[16]	TANG R, XU J, ZHANG B, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity[J]. J Hematol Oncol, 2020, 13(1): 110. DOI: 10.1186/s13045-020-00946-7.
[17]	GAUTHERON J, GORES GJ, RODRIGUES C. Lytic cell death in metabolic liver disease[J]. J Hepatol, 2020, 73(2): 394-408. DOI: 10.1016/j.jhep.2020.04.001.
[18]	COLAK Y, HASAN B, ERKALMA B, et al. Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target[J]. Clin Res Hepatol Gastroenterol, 2021, 45(4): 101710. DOI: 10.1016/j.clinre.2021.101710.
[19]	LOZANO-RUIZ B, GONZÁLEZ-NAVAJAS JM. The emerging relevance of AIM2 in liver disease[J]. Int J Mol Sci, 2020, 21(18): 6535. DOI: 10.3390/ijms21186535.
[20]	AL MAMUN A, WU Y, JIA C, et al. Role of pyroptosis in liver diseases[J]. Int Immunopharmacol, 2020, 84: 106489. DOI: 10.1016/j.intimp.2020.106489.
[21]	WANG Y, GAO W, SHI X, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin[J]. Nature, 2017, 547(7661): 99-103. DOI: 10.1038/nature22393.
[22]	XU W, CHE Y, ZHANG Q, et al. Apaf-1 pyroptosome senses mitochondrial permeability transition[J]. Cell Metab, 2021, 33(2): 424-436. e10. DOI: 10.1016/j.cmet.2020.11.018.
[23]	XU B, JIANG M, CHU Y, et al. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice[J]. J Hepatol, 2018, 68(4): 773-782. DOI: 10.1016/j.jhep.2017.11.040.
[24]	ZHU Y, ZHAO H, LU J, et al. Caspase-11-mediated hepatocytic pyroptosis promotes the progression of nonalcoholic steatohepatitis[J]. Cell Mol Gastroenterol Hepatol, 2021, 12(2): 653-664. DOI: 10.1016/j.jcmgh.2021.04.009.
[25]	MITSUYOSHI H, YASUI K, HARA T, et al. Hepatic nucleotide binding oligomerization domain-like receptors pyrin domain-containing 3 inflammasomes are associated with the histologic severity of non-alcoholic fatty liver disease[J]. Hepatol Res, 2017, 47(13): 1459-1468. DOI: 10.1111/hepr.12883.
[26]	CSAK T, PILLAI A, GANZ M, et al. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis[J]. Liver Int, 2014, 34(9): 1402-1413. DOI: 10.1111/liv.12537.
[27]	GONG Z, ZHANG X, SU K, et al. Deficiency in AIM2 induces inflammation and adipogenesis in white adipose tissue leading to obesity and insulin resistance[J]. Diabetologia, 2019, 62(12): 2325-2339. DOI: 10.1007/s00125-019-04983-x.
[28]	YU X, HAO M, LIU Y, et al. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy[J]. Eur J Pharmacol, 2019, 864: 172715. DOI: 10.1016/j.ejphar.2019.172715.
[29]	MAI W, XU Y, XU J, et al. Berberine inhibits nod-like receptor family pyrin domain containing 3 inflammasome activation and pyroptosis in nonalcoholic steatohepatitis via the ROS/TXNIP axis[J]. Front Pharmacol, 2020, 11: 185. DOI: 10.3389/fphar.2020.00185.
[30]	RUAN S, HAN C, SHENG Y, et al. Antcin A alleviates pyroptosis and inflammatory response in Kupffercells of non-alcoholic fatty liver disease by targeting NLRP3[J]. Int Immunopharmacol, 2021, 100: 108126. DOI: 10.1016/j.intimp.2021.108126.
[31]	ZHU P, PENG Y, WU LL, et al. Research progress on the involvement of pyroptosis in nonalcoholic fatty liver disease[J]. Chin Hepatol, 2021, 26(11): 1290-1293. DOI: 10.14000/j.cnki.issn.1008-1704.2021.11.026. 朱鹏, 彭旸, 吴莉莉, 等. 细胞焦亡参与非酒精性脂肪性肝病的相关研究进展[J]. 肝脏, 2021, 26(11): 1290-1293. DOI: 10.14000/j.cnki.issn.1008-1704.2021.11.026.
[32]	DEWIDAR B, MEYER C, DOOLEY S, et al. TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019[J]. Cells, 2019, 8(11): 1419. DOI: 10.3390/cells8111419.
[33]	WU J, LIN S, WAN B, et al. Pyroptosis in liver disease: New insights into disease mechanisms[J]. Aging Dis, 2019, 10(5): 1094-1108. DOI: 10.14336/AD.2019.0116.
[34]	INZAUGARAT ME, JOHNSON CD, HOLTMANN TM, et al. NLR family pyrin domain-containing 3 inflammasome activation in hepatic stellate cells induces liver fibrosis in mice[J]. Hepatology, 2019, 69(2): 845-859. DOI: 10.1002/hep.30252.
[35]	GAUL S, LESZCZYNSKA A, ALEGRE F, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis[J]. J Hepatol, 2021, 74(1): 156-167. DOI: 10.1016/j.jhep.2020.07.041.
[36]	GUO B, FU S, ZHANG J, et al. Targeting inflammasome/IL-1 pathways for cancer immunotherapy[J]. Sci Rep, 2016, 6: 36107. DOI: 10.1038/srep36107.
[37]	ZHANG X, LI C, CHEN D, et al. H. pylori CagA activates the NLRP3 inflammasome to promote gastric cancer cell migration and invasion[J]. Inflamm Res, 2022, 71(1): 141-155. DOI: 10.1007/s00011-021-01522-6.
[38]	GARCÍA-PRAS E, FERNÁNDEZ-IGLESIAS A, GRACIA-SANCHO J, et al. Cell death in hepatocellular carcinoma: Pathogenesis and therapeutic opportunities[J]. Cancers (Basel), 2021, 14(1): 48. DOI: 10.3390/cancers14010048.
[39]	YAN H, LUO B, WU X, et al. Cisplatin induces pyroptosis via activation of MEG3/NLRP3/caspase-1/GSDMD pathway in triple-negative breast cancer[J]. Int J Biol Sci, 2021, 17(10): 2606-2621. DOI: 10.7150/ijbs.60292.
[40]	ZHOU CB, FANG JY. The role of pyroptosis in gastrointestinal cancer and immune responses to intestinal microbial infection[J]. Biochim Biophys Acta Rev Cancer, 2019, 1872(1): 1-10. DOI: 10.1016/j.bbcan.2019.05.001.
[41]	HUANG DQ, EL-SERAG HB, LOOMBA R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(4): 223-238. DOI: 10.1038/s41575-020-00381-6.
[42]	CHEN YF, QI HY, WU FL. Euxanthone exhibits anti-proliferative and anti-invasive activities in hepatocellular carcinoma by inducing pyroptosis: preliminary results[J]. Eur Rev Med Pharmacol Sci, 2018, 22(23): 8186-8196. DOI: 10.26355/eurrev_201812_16511.
[43]	WEI Q, MU K, LI T, et al. Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression[J]. Lab Invest, 2014, 94(1): 52-62. DOI: 10.1038/labinvest.2013.126.
[44]	WEI Q, ZHU R, ZHU J, et al. E2-induced activation of the NLRP3 inflammasome triggers pyroptosis and inhibits autophagy in HCC cells[J]. Oncol Res, 2019, 27(7): 827-834. DOI: 10.3727/096504018X15462920753012.
[45]	ZHANG Y, YANG H, SUN M, et al. Alpinumisoflavone suppresses hepatocellular carcinoma cell growth and metastasis via NLRP3 inflammasome-mediated pyroptosis[J]. Pharmacol Rep, 2020, 72(5): 1370-1382. DOI: 10.1007/s43440-020-00064-8.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (2095) PDF downloads(171)

Role of pyroptosis in nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.01.027

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Role of pyroptosis in nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.01.027

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content